Jason Crosson

Dr. Jason Crosson


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Ophthalmology and Eye Diseases
Verified
Journal Article
Open access
JCJason Crosson
Jason Crosson
LMLauren Mason
Lauren Mason
JMJohn O Mason
John O Mason
Introduction: To review important studies examining focal laser for diabetic macular edema (DME), to examine real-world data regarding actual treatments patients are receiving, to present long-term visual outcomes in real-world practice, and to suggest an evidence-based approach for the use of focal laser. Methods: This study is a review of landmark studies evaluating focal laser and pharmacologic therapy for DME. In addition, the authors include a retrospective review of 102 consecutive eyes of 53 patients in our practice setting in rural Alabama. A chart review was performed, and patients were included if they were diagnosed with DME and were treated with both focal laser and bevacizumab. Bevacizumab and focal laser were given on a “as needed basis” at the discretion of one treating physician (J.O.M.). Worse visual acuity or worsening macular edema were indications for additional treatment. Statistical analysis was performed using frequencies and percentages. Best-corrected visual acuity (BCVA) was recorded at baseline and at the end of treatment (mean of 5 years) in the medical record. Primary outcome measures were BCVA, patients with better than 20/40 BCVA, patients with worse than 20/200 BCVA, and patients with stable BCVA. Results: Anti–vascular endothelial growth factor (VEGF) therapies are the first-line treatment for DME, but real-world claims data suggest that diabetic patients cannot come in for monthly injections as in large clinical trials. In our series, after a mean of 5 lasers and 5.5 injections, 90% of eyes had stable or better BCVA, 65% were ≥20/40, and only 13% were ≤20/200. Conclusions: Laser treatment for DME remains an important adjunctive therapy

29 December 2022 in American Journal of Ophthalmology Case Reports
Verified
Journal Article
Open access
NFNathan A. Fischer
Nathan A. Fischer
RWRobert C. Wann
Robert C. Wann
JCJason Crosson
Jason Crosson
To report a case of acute posterior multifocal placoid pigment epitheliopathy (APMPPE) following COVID-19 infection. A 17-year-old female developed central scotomas and photopsias two weeks after SARS-CoV-2 diagnosis with polymerase chain reaction studies. She presented with poor visual acuity of 3/60 on the Feinbloom eye chart in the left eye. Dilated examination and multi-modal retinal imaging were consistent with the diagnosis of APMPPE, with noteworthy subretinal fluid. The patient was treated with an oral prednisone taper starting at 60mg with rapid resolution in subretinal fluid and improvement of visual acuity. Five weeks after presentation, visual acuity improved to 20/20 OU with complete resolution of the creamy white choroidal lesions and subretinal fluid. There is a growing body of literature reporting the ocular manifestations of COVID-19. Rarely inflammation of the retina or choroid have been associated with the infection. To the best of our knowledge, there are no prior reports that describe the clinical course or visual outcome in a patient with APMPEE associated with recent COVID-19 infection. Accordingly, we are not aware of any other reports that describe the treatment of APMPEE associated with COVID-19 with corticosteroids. The mechanism linking COVID-19 infection to inflammatory ocular disorders in unclear and likely multi-factorial.

1 January 2021 in Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
MTMeredith E. Thomley
Meredith E. Thomley
CGCole N. Gross
Cole N. Gross
APAna Preda-Naumescu
Ana Preda-Naumescu
KCKelly S. Chen
Kelly S. Chen
TSThomas Swain
Thomas Swain
JCJason Crosson
Jason Crosson
The purpose of this study was to assess outcomes in a real‐world nonclinical trial setting of antivascular endothelial growth factor (VEGF) injections alone vs. focal laser combined with anti‐VEGF injections in patients with branch retinal vein occlusion‐ (BRVO‐) related macular edema (ME). This study included 88 BRVO with ME patients who were treated over three years at both a tertiary referral center in the Birmingham metropolitan area and satellites in rural Alabama. One group received only anti‐VEGF injections ( n = 56); the other group received both anti‐VEGF injections and focal laser ( n = 32). The following outcome measures were evaluated: initial and final visual acuities (VA), initial central subfield thickness (CST) on OCT, number of injections, number of lasers, percentage of patients with a gain of 3 lines of VA, percentage of patients with VA better than or equal to 20/40, and percentage of patients with VA worse than or equal to 20/200. We found that there was no difference in initial VA ( p = 0.913) or CST ( p = 0.961) between the two groups. The injection only group required a median of 7 injections, while the combination group required a median of 4 injections, but this was not a statistically significant difference ( p = 0.117). There was no difference in final VA ( p = 0.414) or any of the other visual outcomes between the two groups. In conclusion, focal laser did not decrease the number of injections required or improve the VA in BRVO‐related ME. Although visual outcomes were similar in both groups, focal laser does not appear to be of additional benefit in BRVO‐related ME in the anti‐VEGF era.

1 August 2019 in Ophthalmology Retina
Verified
Journal Article
Closed access
JCJason Crosson
Jason Crosson
TSThomas A. Swain
Thomas A. Swain
MCMark E. Clark
Mark E. Clark
CHCarrie E. Huisingh
Carrie E. Huisingh
GMGerald McGwin
Gerald McGwin
CCChristine Curcio
Christine Curcio

6 April 2017 in Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
LMLauren Mason
Lauren Mason
JCJason Crosson
Jason Crosson
JMJohn O. Mason
John O. Mason
GMGerald McGwin
Gerald McGwin
Purpose. To identify treatment preferences of patients with diabetic macular edema (DME) having undergone laser and intravitreal injections. Methods. Patients with DME who received lasers and injections were surveyed, measuring preferences toward specific treatments. 66/210 diabetic patients met the criteria for our survey assessing preference for lasers and/or injections, incorporating demographics and treatment preference questions. Outcome measures included treatment preference (laser or injections), how often patients are willing to be treated, and how much vision they will sacrifice to avoid being treated every month. Results. 66 patients completed the survey. The mean diabetes duration was 20.7 years, the mean retina follow-up was 4.4 years, and patients received a mean of 4.82 lasers and 4.86 injections. 56% preferred injections, 33% preferred laser, and 11% had no preference. Regarding treatment effectiveness, 38% found no difference, 36% chose laser, and 25% chose injections. Regarding anxiety, 56% reported injection anxiety. While 50% versus 38% reported that laser was easier than injections. 91% would give up zero lines on the eye chart, and 76% would come in 12 times yearly for treatment to maintain vision. Conclusion. Patients with DME have no profound preference regarding laser versus intravitreal injections but prefer aggressive treatment and are unwilling to sacrifice vision for less visits.

1 November 2019 in Ophthalmic Surgery, Lasers and Imaging Retina
Verified
Journal Article
Closed access
PDF file
LMLauren B. Mason
Lauren B. Mason
JWJames B. Wilhite
James B. Wilhite
GMGerald McGwin
Gerald McGwin
TSThomas A. Swain
Thomas A. Swain
JCJason Crosson
Jason Crosson
BACKGROUND AND OBJECTIVE: Patients with hemorrhagic posterior vitreous detachments (HPVDs) have a high rate of retinal tears and often develop retinal detachments (RDs). This study aims to compare outcomes of 25-gauge pars plana vitrectomy (PPV) for HPVD versus an observational group. PATIENTS AND METHODS: Retrospective cohort study of 109 consecutive eyes of 105 patients diagnosed with HPVD; 66 eyes underwent PPV and 43 eyes were observed. RESULTS: Twenty-four eyes (36.4%) in the surgical group were found to have tears intraoperatively not seen preoperatively. The median time to vitreous hemorrhage (VH) resolution was significantly shorter for the PPV group, 14 days (interquartile range [IQR]: 7 days to 35 days), compared to those who were observed, 58.5 days (IQR: 30 days to 91 days) (P < .0001). RDs occurred more frequently among observational patients (11.63%) compared to 1.52% of surgical patients (P = .0344). CONCLUSION: Twenty-five-gauge PPV for HPVD resulted in less RDs, diagnosis of occult retinal breaks intraoperatively, and shorter time to VH resolution. [Ophthalmic Surg Lasers Imaging Retina. 2019;50:e288–e293.]